Key Organics and RBC Announce Library Screening Format
News Jun 01, 2006
Beginning this summer, the entire Key Bionet library of 37,500 diverse drug-like compounds will be offered for "rental" screening on RBC’s DiscoveryDot™ platform.
Customers will be able to screen the Key library without having to purchase it outright.
"While we have many large pharma clients who wish to purchase compounds directly, we see an unmet need in smaller pharma and biotech companies that want to screen one or more of their targets without investing in a library purchase," said Colin Piper, Business Development Manager for Key.
"RBC’s platform gave us an economical way to reach these potential customers. Now researchers who do not have a budget for library purchases can still afford library screening."
The Key library will be screened locally at RBC’s lab facilities in Malvern PA. RBC will reformat the library to its microarray-based platform.
"Our nanoliter-scale screening process means that we can we offer lower costs to customers, while our partnership with Key provides a clear path to additional chemistry expansion," said Tom Festa, National Sales Manager for RBC.
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE